Larger models can pull off a wider variety of feats, but the reduced footprint of smaller models makes them attractive tools.

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...